RxDoctor Payments DataLook up a doctor →

Elmer Stout, MD

Internal Medicine · Mooresville, NCNPI 1851370282

Payments from drug & device makers

$699,209in general payments, 2019–2025

Across 748 payments — averaging $934.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$656K
  • American Regent$17K
  • Novo Nordisk AS$14K
  • Sanofi$2K
  • AbbVie$1K
  • Novo Nordisk$1K
  • plus $7K from 53 others
$9,812in research payments, 2019–2025

Across 4 payments — averaging $2453.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • American Regent$10K

What the payments were for

  • Food & beverage$10,34298%
  • Education$2382%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen93$655,873
American Regent10$17,222
Novo Nordisk AS8$14,177
Sanofi2$2,325
AbbVie(2 entities)121$1,483
Novo Nordisk84$1,159
Pfizer59$887
Boehringer Ingelheim42$603
Lilly USA, LLC30$473
Astellas Pharma US Inc20$439
Eisai Inc.25$361
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC24$327
Novartis17$292
Bayer18$256
AstraZeneca15$233
Merck14$228
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)13$213
Takeda Pharmaceuticals U.S.A., Inc.14$201
Sumitomo Pharma America, Inc.7$172
Lundbeck LLC8$167
Sanofi-aventis U.S. LLC9$166
E.r. Squibb & Sons, L.L.C.9$165
Johnson & Johnson12$158
Axsome Therapeutics, Inc.9$152
Amarin Pharma, Inc.7$93
Exact Sciences5$87
Daiichi Sankyo Inc.4$86
Supernus Pharmaceuticals, Inc.4$85
SK Life Science, Inc.5$81
Kowa Pharmaceuticals America, Inc.5$75
GSK4$70
Shire North American Group Inc5$69
Arbor Pharmaceuticals, Inc.4$67
Esperion Therapeutics, Inc.4$66
Pacira Therapeutics, Inc.3$65
Radius Health, Inc.3$57
Mylan Specialty L.p.3$56
Biohaven Pharmaceutical Holding Company Ltd.3$51
Abbott3$50
IBSA Pharma Inc.3$47
Boston Scientific2$37
Zimmer Biomet1$34
Vanda Pharmaceuticals Inc.1$27
Neurocrine Biosciences, Inc.1$26
Avion Pharmaceuticals1$24
Dexcom, Inc.1$23
Azurity Pharmaceuticals, Inc.1$21
Irhythm Technologies, Inc.1$20
Idorsia Pharmaceuticals US Inc1$19
Ardelyx, Inc.1$19
Advanced Respiratory, Inc1$18
Tolmar, Inc.1$16
Phathom Pharmaceuticals, Inc.1$14
Actelion Pharmaceuticals US, Inc.1$14
Romark Laboratories, LC1$14
Therapeuticsmd, Inc.1$12
Teva Pharmaceuticals USA, Inc.1$12
Neos Therapeutics, LP1$11
Corium, LLC1$11

How this compares

$699,209 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$144,035
Medicare patients
256
Services billed
2,010

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban148$133,162
JardianceEmpagliflozin85$87,688
OzempicSemaglutide65$61,654
MounjaroTirzepatide53$57,573
Repatha SureclickEvolocumab69$48,973
FarxigaDapagliflozin Propanediol41$47,174
XareltoRivaroxaban36$30,057
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$30,028
MyrbetriqMirabegron55$29,222
ProliaDenosumab14$23,900
LinzessLinaclotide26$23,199
TrulicityDulaglutide19$21,011
RybelsusSemaglutide15$17,487
Sucralfate203$16,783
GlyxambiEmpagliflozin/Linagliptin15$16,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$887$133,162148 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$603$120,109126 claims
Novo NordiskOzempic, Rybelsus$1,159$79,14280 claims
Lilly USA, LLCMounjaro, Trulicity$473$78,58472 claims
AstraZenecaFarxiga, Symbicort$233$56,51967 claims
Johnson & JohnsonXarelto, Invokana$158$37,54047 claims
AbbVieLinzess, Creon, Synthroid$1,483$35,46486 claims
GSKTrelegy Ellipta$70$30,02838 claims
Astellas Pharma US IncMyrbetriq$439$29,22255 claims
AmgenProlia$655,873$23,90014 claims
Sumitomo Pharma America, Inc.Gemtesa$172$15,74114 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$201$12,58416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Mooresville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →